Tegileridine plus intercostal nerve block for pain after thoracoscopic lung removal

Study on the Analgesic Effect of Tegileridine Combined With Intercostal Nerve Block After Thoracoscopic Lung Resection

This trial will test whether giving a local intercostal nerve block together with patient-controlled tegileridine improves pain control for adults having thoracoscopic lobectomy or segmentectomy.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 118 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Tongji Hospital (Academic / other)
• Locations: 1 site (Wuhan, Hubei)
• Trial ID: NCT07386626 on ClinicalTrials.gov

What this trial studies

This single-center interventional study at Tongji Hospital combines an early intercostal nerve block (ICNB) with patient-controlled intravenous tegileridine to cover both immediate incision pain and later central/visceral pain after thoracoscopic lung resection. Patients receive perioperative ICNB and postoperative patient-controlled analgesia with tegileridine, with interventions listed to include sufentanil as a comparator or reference analgesic. The approach aims to provide rapid incision analgesia from the block and sustained central analgesia from tegileridine while reducing common opioid side effects. Primary outcomes will focus on postoperative pain scores, opioid consumption, recovery metrics, and incidence of chronic post-surgical pain.

Who should consider this trial

Good fit: Adults aged 18–75 undergoing elective thoracoscopic lobectomy or segmentectomy with ASA I–III and BMI 18–30 who can give informed consent are the intended participants.

Not a fit: Patients who are pregnant or breastfeeding, have severe respiratory or cardiovascular disease, severe liver or kidney dysfunction, sleep apnea, opioid dependence, allergies to study drugs, or other major contraindications are excluded and unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the combination could give faster and more stable pain relief after thoracoscopic lung surgery, speed recovery, reduce opioid side effects, and lower the risk of chronic post-surgical pain.

How similar studies have performed: Multimodal approaches that combine regional nerve blocks with systemic analgesics have previously reduced acute pain and opioid use after thoracic surgery, although tegileridine itself is less widely studied than standard opioids.

Eligibility criteria

Inclusion Criteria:

* Age range: 18 to 75 years old;
* Patients undergoing elective thoracoscopic lobectomy or segmentectomy;
* ASA classification levels I-III;
* BMI 18 \~ 30 kg/m2。
* Voluntarily participate and sign an informed consent form.

Exclusion Criteria:

* Patients with preoperative alcohol dependence and long-term use of analgesic drugs are receiving analgesic treatment for other acute and chronic pain;
* Pregnant or lactating women;
* Allergies or other contraindications to the anesthetics, analgesics, and antiemetic drugs used in the study;
* Patients with severe sleep apnea syndrome or acute or severe bronchial asthma;
* Suffering from mental and neurological disorders or cognitive impairment, known or suspected gastrointestinal obstruction, severe liver and kidney dysfunction (Child Pugh score C), chronic obstructive pulmonary disease or severe cardiovascular disease, etc;
* Researchers consider participants who are not suitable to participate in this study and those who refuse to participate.

Where this trial is running

Wuhan, Hubei

• Tongji hospital — Wuhan, Hubei, China (Recruiting)

Study contacts

• Study coordinator: Aijun Xu, Dr.

Conditions Lobectomy